Introduction
Malignant transformation is often associated with an aberrant expression of certain types of cell-surface proteins,f or example, receptors, cell adhesion molecules, or proteins active in embryonic development. [1] Molecular recognition of these proteins can be used fors pecific treatment of malignant cells, for example, targeted therapy.M onoclonal antibodies (Mabs) are the most used kind of targeting agents, which may act by preventingm itogenic signaling [2] or by eliciting antibody-dependent or complement-dependent cytotoxicity. [3] Antitumor action of Mabs might be furthere nhanced by conjugation of cytotoxic drugs or radionuclides. [4] However,t here is an appreciable inter-and intrapatient heterogeneity in expression of molecular targets. Apparently,t umors that do not express particular targets would not respondt oaparticular targeting therapy.T herefore, the targeted treatment should be personalized, that is, adjusted to the tumor molecular abnormality profile of each particularc ancer case. [5] In vivo visualization of cellsurfacet arget proteins using radionuclide molecular imaging can personalize anticancert reatment by the selection of patients who would mostl ikely benefit from ap articular targeted therapy. [6] Ap ossible approacht ot he development of imaging agents is the radiolabeling of therapeutic Mabs using nuclides emitting gamma quanta that can be detected outside the patient's body. [7] The use of Mabs as imaging agentsh as, however,c ertain downsides. Antibodies are relativelyb ulky proteins (150 kDa);t his limits their rates of extravasation, tumor penetration,a nd blood clearance of unboundt racers. [7, 8] Therefore, imaging is possible only several days after injection. In addition, antibodies have at endency to accumulate in tumors nonspecifically due to an "enhanced permeability and retention" (EPR) effect, which might cause false positive diagnoses. [7] Small engineered scaffold affinity proteins, for example, Affibody molecules, are stronga lternatives to antibodies in the development of imaging agents. [9] Affibody molecules are small (7 kDa) three-helical cysteine-free scaffold proteins derived from the immunoglobulin-binding Bdomain of staphylococcal receptor protein A. [10] Randomization of surfacea mino acids on helices 1a nd 2o fA ffibody molecules createsl arge combinatorial libraries enabling the selection of high-affinity binderst od ifferent proteins, including cancer-associated ones. [10] The small size and high affinity (in low nanomolar and subnanomolar range) makes them good candidates for development of imaging probes. [11] Affibody-based agents have been generated for the imaging of several cancer-associated molecular targets, for example human epidermal growth factor receptor type 2( HER2), [12] insulin-like growth factor-1 receptor Affibody molecules are small scaffold-based affinity proteins with promisingp roperties as probes for radionuclide-based molecular imaging. However,ahigh reabsorption of radiolabeled Affibody molecules in kidneys is an issue. We have shown that the use of 125 I-3-iodo-((4-hydroxyphenyl)ethyl)maleimide( IHPEM) for site-specific labeling of cysteine-containing Affibody molecules provides high tumor uptake but low radioactivity retention in kidneys. We hypothesized that the use of 4-iodophenethylmaleimide (IPEM) would further reduce renal retention of radioactivity because of higher lipophilicity of radiometabolites. An anti-human epidermal growth factor receptor type 2( HER2) Affibody molecule (Z HER2:2395 )w as labeled using 125 I-IPEM with an overall yield of 45 AE 3%.
125 I-IPEM-Z HER2:2395 bound specifically to HER2-expressing human ovarian carcinoma cells (SKOV-3 cell line). In NMRI mice, the renal uptake of 125 I-IPEM-Z HER2:2395 (24 AE 2a nd 5.7 AE 0.3 %IAg À1 at 1a nd 4hafter injection, respectively)w as significantly lower than uptake of 125 I-IHPEM-Z HER2:2395 (50 AE 8a nd 12 AE 2% IA g À1 at 1a nd 4hafter injection, respectively). In conclusion, the use of am ore lipophilic linker for the radioiodination of Affibody molecules reduces renal radioactivity.
(IGF-1R), [13] platelet derived growth factor beta (PDGFb), [14] epidermal growth factor receptor (EGFR), [15] and carbonic anhydrase IX (CAIX). [16] Preclinical studies have demonstrated that Affibody molecules provide am uch higherc ontrast than radiolabeled Mabs and enable imaging only af ew hours after injection. [17] Clinical studies have demonstrated the capacity of Affibody molecules to image HER2 expression in breast cancer metastases. [18, 19] The major excretion route of Affibody molecules is renal due to their small size. After glomerular filtration, Affibody molecules undergo nearly quantitative reabsorption in the renal tubuli cells followed by internalizationa nd lysosomal degradation. The use of residualizing radiometal labels results in al ong retention of radioactivity in kidneys. This phenomenon wasobserved for Affibody molecules specific to different targets,f or example, HER2, IGF-1R, EGFR, and PDGFRb,a nd labeled with different radiometalsu sing different chelators. [13, 14, 15, 20, 21] The high renal retention is am ajor dosimetry problem in the case of radionuclide therapy and might complicate imaging of metastases in the lumbar region.Ont he other hand, radiocatabolites are cleared rapidly from kidneys when Affibody molecules are labeled using nonresidualizing halogens, such as 18 F, [22, 23, 24] 76 Br, [25] or different iodine radioisotopes. [17, 26, 27] Importantly,i nternalization of receptor-bound Affibody molecules by cancer cells is slow, [13, 14, 15, 28] which makes residualizing properties of al abel not critical for successful targeting. Thus,t he use and further development of nonresidualizing labels is apromising way to reduce renal retention of radioactivity of radiolabeled Affibody molecules.
Among radiohalogens, iodine radioisotopes offer av ariety of properties as labels for targeting proteins and peptides;f or example, 123 I( t 1 = 2 = 13.3 h) is suitable for imaging using singlephoton emission computed tomography( SPECT), 124 I( t 1 = 2 = 4.18 d) for positron emission tomography (PET), and 131 I( t 1 = 2 = 8d)f or therapy.T he long-lived 125 I( t 1 = 2 =59.4 d) is ac onvenient surrogate nuclide, which is commonly used in the development of radioiodination techniques. Direct radioiodination of Affibody molecules destroys binding, presumably due to the presence of tyrosine in the binding site. [28] To overcome this problem,A ffibody molecules were indirectly labeled using Nsuccinimidyl para-iodobenzoate (SPIB) as ap recursor. [12] The resulting 125 I-para-iodobenzoate ( 125 I-PIB)-Z HER2:342 has demonstrated high-contrast imaging of HER2-expressing xenografts in mice and low renal retention of radioactivity.Ad isadvantage of that methodi st hat it is not site-specific. There are seven amino groups in Z HER2:342 (N-terminus and six lysines), which result in am ixture of proteins with ad ifferent number of labeled prosthetic groups per protein at different positions. A meta-analysis of biodistribution studies suggested that the biodistribution profile of ( 125 I-PIB)-Z HER2:342 was not quite reproducible, possibly because of some deviation in labeling conditions resultingi nd ifferent compositions of such amixture. [26] The introductiono fau nique thiol group by engineering acysteine into the Affibody molecule allows asite-specific coupling of al inker molecule by thiol-directed chemistry.B othi ndirect radiohalogenation of cysteine-containing Affibody molecules using 3-bromo-(4-hydroxyphenethyl)maleimide (BrHPEM) or 3-iodo-(4-hydroxyphenethyl)maleimide (IHPEM) (1,F igure 1) as an intermediate precursor resulted in ah omogenous radiolabeled product with preserved binding specificity. [25, 27] Surprisingly,t he use of BrHPEM and IHPEM resulted in four to sevenfold decrease of renal retention of radioactivity at 4h after injection, in comparison with the use of para-halobenzoatebased labels. This demonstrated that positioning of the linker molecule influences the biodistribution profile. However,t he exact mechanism of the decrease is not clear.W es peculate that exoproteases are predominantly featured in the renal proteolysiso fA ffibody molecules, andaterminal placement results in am ore rapid formation of "leaky" lipophilic radiometabolites. As lipophilicity of radiometabolites is an important factor in their decreased intracellularr etention, [29] the use of am ore lipophilic pendant group for C-terminal radioiodination of cysteine-containing Affibody molecules should further reduce renal retention of radioactivity. N-(4-[
, which has been earlier developed for site-specific labeling of antigen-bindingf ragments (Fab fragments), [30] would be as uitable linker,a si tb oth permits site-specific labeling of cysteine-containingA ffibody molecules and is more lipophilic than IHPEM.
The goalo ft his study was to test hypothesis that the use of 125 I-IPEM for indirect radioiodination of Affibody molecules provides ac onjugate that is capable of specific binding to its molecular target cells and provides lower renal retention of radioactivity than its 125 I-IHPEM-labeled counterpart. The anti-HER2 Affibody molecule Z HER2:2395 with aC -terminal cysteinew as used as am odel in this study.L abeling of Z HER2:2395 using 125 I-IPEM was established, and properties of 125 I-IPEM-Z HER2:2395 and 125 I-IHPEM-Z HER2:2395 were directly compared in vitro and in vivo.
Results and Discussion
Synthesis of ap recursor for iododestannylation, N-[4-(tri-n-butylstannyl)phenethyl]-maleimide (7), was performed according to Scheme 1. 4-Bromophenethylamine (3)w as protected with phthalimde using phthalic anhydride and provided 4 in 81 %. Ap alladium-catalyzed metal-halogen exchangeu sing bis(tributyltin)y ielded 5 in 83 %. Deprotection of the phthalamide group using methylamine( 94 %y ield) and as ubsequentr eaction with malemide provided 7 in 30 %. Synthesis of nonradioactive iodophenethylmaleimide (8) f or the use as ac hroma- 
Radioiodination of 7
Precursor 7 was radioiodinated using Chloramine-T as an oxidant (Scheme 3). As our goal was "one-pot" labeling, that is, performing radioiodination of ap recursor and conjugation of radio-IPEMt op rereduced Affibody molecules without intermediate purification, we tried to determine am inimum amount of 7 that provides as table high yield. In the first series of labeling experiments, the amount of 7 dissolved in ethanol was varied, while the amounto fo xidantw as constant (40 mg, 140 nmol) and reaction time was 10 min. The influence of the amount of 7 on labeling yield is shown in Figure 2 . Between 0.01 mg( 0.02 nmol) to 1 mg( 2nmol) the labeling yield increasedp roportionally with the amount of added precursor, from 31 AE10 %upto71.9 AE 0.4 %. An additional amount of precursor up to 12 mg(24 nmol) did not further improvet he labeling yield significantly.I nab lank experiment where only solvent (5 %a cetic acid in methanol) wasu sed, no labeling yield could be determined ( Figure 3 ).
Iododestannylation of 7 was apparently rapid (Figure 4 ). When 3 mg( 6nmol) of 7 was used, ay ield of 73 AE 3% was obtained already after 1min,a nd furtherp rolongation of the reaction time did not increaset he yield significantly.
For further labeling experiments, the following conditions were selected:2m g( 4nmol) of 7,4 0m g( 140 nmol) of Chloramine-T,and areactiontime of 2min. The conjugation of 125 I-IPEM to ap rereduced Z HER2:2395 was performed using ao ne-pot two-step approach, that is, in the same reaction vial as iododestannylation without purification of 2.T he coupling yield of 125 I-IPEM to Z HER2:2395 was measured by varying Affibody:IPEM molar ratios (1:1, 2:1, and 3:1). The samples were analyzed at 20, 40, and 60 min. The overall labeling yield (i.e. incorporation of radioiodine into Affibody molecules) after 20 min incubation was 21 AE 2% and 43 AE 4% for Affibody:IPEM ratios of 1:1a nd 2:1, respectively.T he highest overall yield, 53 AE 1%,w as obtained at the ratio of 3:1 ( Figure 5 ). Since the difference between ratios 2:1a nd 3:1w as small, the ratio of 2:1w as used for preparation of conjugates for in vivo and in vitro experimentsi no rder to keep ah igher specific activity of the conjugate. Given that the yield remained reasonably constant fort he three time points, the incubation time was set to 40 min. According to instant thin-layer chromatography (ITLC) analysis, purification of 125 I-IPEM-Z HER2:2395 using aN AP-5 size-exclusion column provided ar adiochemical purity of 98.9 AE 0.5 %.
The radioiodination of 125 I-IHPEM-Z HER2:2395 resulted in an overall labeling yield of 45 AE 3% at an Affibody:HPEM molar ratio of 2:1a nd ar adiochemicalp urity of 99 %a fter separation on an NAP-5 size exclusion column.
Stability test
To ensure that radioiodine is attached to the Affibody molecules via as table covalent bond, samples of 125 I-IPEM-Z HER2:2395 were incubated up to 4h in 2 m of sodium iodide to replacen oncovalently bound 125 Ia nd in 30 % ethanol to displace an oncovalently bound 2.I ncubation in sodium iodide resulted in aradiochemicalp urity of 98.5 AE 0.1 %, and incubation in 30 %e thanol in ap urity of 99.4 AE 0.1 %. The purity of control samples, which were kept in phosphate-buffered saline (PBS) was 99.4 AE 0.1 %, that is, the difference was within experimental accuracy.K eeping samples in PBS for 24 ha t4 8 Ca nd 37 8Cr esulted in ap urity of 97.3 AE 2.1 %a nd 99.3 AE 0.3%,r espectively.
In vitro studies
To verify that the binding of the labeled Z HER2:2395 was specific to HER2 receptors, the labeled Affibody conjugates were incubated with aH ER2-overexpressingh uman ovarian carcinoma cell line (SKOV-3) presaturated with nonlabeled Z HER2:2395 .S aturation of HER2 caused significant (p < 0.00005) decrease of cellbound activity,f rom 53.7 AE 0.9 %t o2 .6 AE 0. (8 h). The level of internalized radioactivity was low (below 10 %) during whole observation period for both conjugates.
Biodistribution studyinm ice
Comparison of 125 I-IPEM-Z HER2:2395 and 125 I-IHPEM-Z HER2:2395 biodistribution in NMRI mice is shown in Ta ble 1a nd Figure 8 . A common feature of both variantsw as rapid clearance from blood (less than 3% injected activity (IA) g À1 at 1h and less than 1% IA g À1 at 4hpostinjection (pi)). It has to be noted that blood concentration was significantly (p < 0.05) lower for 125 I-IHPEM-Z HER2:2395 at all time points. Clearance from other organs and tissues was also rapid. Importantly,t he renal uptake of 125 I-IHPEM-Z HER2:2395 ), the differenced isappeared by 4h pi (1.4 %IAg À1 for both conjugates).O fn ote is the significantly higherr adioactivity in the gastrointestinal tract (with content) for 125 I-IHPEM-Z HER2:2395 , which indicates that al arger fraction of this conjugate or its radiometabolites is excreted via bile.
Discussion
Engineered scaffold proteins such as Affibody molecules, are an emerging alternative to Mabs in radionuclide tumor targeting for diagnostics and therapy.Apreconditionf or successful clinicala pplication of scaffold proteins is maximizing the delivery and retention of radionuclides in tumors and minimizing their delivery and retention in normalt issues. In the case of imaging, this provides higherc ontrast and, therefore, sensitivity.I nt he case of radionuclide therapy,t his ensures destruction of tumors while sparingn ormalt issues.H ence, ad ecrease in uptake and retention of radionuclides in normal tissues is as important as an increase in tumor uptake.T his study focused on the decrease of renal radioactivity delivered by Affibody molecules.
The decrease in renal radioactivity might be achieved, in principle, by the decrease in renal reabsorption of targeting proteins or by the decrease in retention of radiocatabolites in proximal tubuli cells. Previous studies [31] have demonstrated that the scavenger receptor megalin is not involved in renal reabsorption of Affibody molecules. Therefore, common methods for the decrease in renal reabsorption of small proteins and peptides in kidneys, e.g. saturation (27 pM) were incubated at 37 8C. Acid wash was used to determine the membranebound radioactivity.C ell-bound activity is normalized to the maximum uptake. Data are presented as mean value AE S.D. (n = 3). Error bars might not be seen because they are smaller than the point symbols. www.chemistryopen.org of scavenger receptors by co-or preinjection of cationic amino acids or Gelofusine, do not work. Therefore, minimization of retention of radiocatabolites in proximal tubuli is the only viable alternative at the moment. Our previous studies have demonstrated that this goal might be achieved for both radiohalogens [25, 27] and for such radiometals as 99m Tc [32, 33] and radioisotopes of rhenium. [34, 35] It has to be admitted that such decrease was achieved as ar esult of structure-property relationship studies, and molecular andb iological mechanismsl eading to this are still not quite clear for us. This study should elucidate the effecto fl ipophilicity of ap rosthetic group, used in the attachment of ar adiohalogen to an Affibody molecule, on renal retention.
Synthesis of 125 I-IPEM for the labeling of Fab fragments was reported by Hylarides and co-workers in 1991. [30] Factors influencing labeling efficiency were described in the initial report. Unfortunately,w ed id not find anyf ollow-up studies concerning this interesting precursor for radioiodination.
125 I-IPEM attracted our attention because it is suitable for thiol-directed site-specific labeling of cysteine-containingA ffibody molecules and its hydrophobicity (log P = 2.85) is higher than that of 125 I-IHPEM (log P = 2.46).
Iododestannylation of 7 was efficient, enabling ay ield in excess of 70 %w hen 1-3 mg( 2-6 nmol) was used for labeling ( Figure 2) . The reactionw as rapid, and the high yield was achieved within 1min (Figure 4) , when 3 mgo f7was used. The efficient labeling of as malla mounto fp recursor removed the need for the intermediate purification of 2,i .e. we can perform the whole conjugation "in one pot". This approach minimizes the handling of radioactive compounds, the associated dose burden to personnel, the losses during transfer of labeled precursor,a nd the probability of human error. [36] The overall labeling yield of the two-step process was am odest~20 %w hen an Affibody:precursor molarratio of 1:1w as used ( Figure 5 ). Increasingthe ratio to 2:1doubled the overall yield, but afurther increasei nr elative protein amount was relatively inefficient. The Affibody:precursor ratio of 2:1w as selected for furtherl abeling to keep ar easonably high specific activity.T he conjugation time of 20-30 min was sufficient to reach the maximum overall yield ( Figure 5 ). Importantly,t he binding of 125 I-IPEM-Z HER2:2395 to HER2-expressing SKOV-3 cells was saturable (Figure 5A) , whichd emonstrates that the binding specificity of the Affibody molecule was preserved after labeling. Binding specificity of the alternative, 125 I-IHPEM-Z HER2:2395 ,h as also been confirmed ( Figure 5B) .
The internalization rate of anti-HER2 Affibody molecules by cancer cellsi sr ather slow and reaches 30-40 %p er day in the case of residualizing labels. [27] This internalization rate corresponds to dailyc ell-surface renewal. In this study the internalized fraction of radioactivity was below 10 %a ta ll time points which reflects nonresidualizing properties of radiocatabolites. After binding to ac ell-surface receptor,afraction of Affibody molecules is internalized, transferred to the lysosomal compartment, and degraded by proteolytic enzymes. Lipophilic radiometabolites diffuse through lysosomal and cellular membranes and leak out from cells. Am aximum cell-associateda ctivity is achieved when the binding rate is equal to the rate of radiocatabolite leakage. In the case of ah igherl eakage rate, the maximum is reached earlier.Acomparison of binding to SKOV-3 cells (Figure 7) shows that the maximum cell-associated activity for 125 I-IPEM-Z HER2:2395 was reached earlier (4 h) than for 125 I-IHPEM-Z HER2:2395 (8 h ). This suggests that 125 I-IPEM provides more "leaky" radiometabolites. It has to be noted that internalization of anti-HER2 Affibody molecules by cancerc ells is rather slow, [20, 21, 28] andt he differencei st herefore relatively small. This complicates in vitro evaluation of an internalization rate, but is favorable for in vivo tumor targeting, as leakage of radiocatabolites has as mall effect on tumor-associated radioactivity. [37] On the other hand, the internalization rate in kidneys is high, and the difference in radiocatabolite leakage rate has to be much more pronounced.
Direct in vivo comparison of 125 I-IPEM-Z HER2:2395 and 125 I-IHPEM-Z HER2:2395 biodistribution in NMRI mice confirmed the main hypothesis of this study ( ). This might be because of the higher overall lipophilicity of 125 I-IPEM-Z HER2:2395 ,ash igher lipophilicity is generally associated with higher liver uptake. [38] However,t he difference disappeared at 4hpi, at ime point relevant for imaging. More disturbing was the 1.5-fold higher blood level of 125 I-IPEM-Z HER2:2395 ,a st his could negatively affect imaging contrast. This phenomenonm ight be associated with the releaseo fr adiometabolites from kidneys to blood or with higher adhesion to blood proteins.A nother interesting feature of 125 I-IPEM-Z HER2:2395 wasl ower radioactivityu ptake in the stomach and salivary gland. As both these organs express the Na + /I À symporter,iti sl ikely that the metabolism of 125 I-IPEM results in the decreased releaseo ff ree radioiodide. Overall, this www.chemistryopen.org study demonstrated the very pronounced influence of ap rosthetic group for radioiodination on the distribution of radioactivity after injection of Affibody molecules.
This information might also be helpful in the development of other imaging probesb ased on engineered scaffold proteins. It has to be noted that this approachisj ustifiedw hen internalization of an imaging agent by cancer cells is slow but internalization by tubuli cells is rapid. In the case of rapid internalization by cancer cells, the use of ap rosthetic group providing lipophilic radiometabolites would decrease tumor accumulation of radioactivity.I nt his case, radioiodination using prosthetic groups providing charged radiometabolites would be recommended. [39] 
Conclusions
The use of amore lipophilic radioiodinelabel at the C-terminus of Affibody molecules is associated with lower renal retention of radioactivity.T his suggests that ac areful selection of the labeling strategy could be used in the modification and optimization of the biodistribution profile of radiohalogenated imaging agents.
Experimental Section Materials

125
Iw as purchased from PerkinElmer (Waltham, USA). Organic solvents were purchased from Merck (Darmstadt, Germany). Chloramine-T (CAT) and Na 2 S 2 O 5 were from Sigma (St. Louis, USA). Buffers, including 0.1 m PBS (pH 7.5) and 0.2 m NH 4 OAc (pH 6.3), were prepared using common methods from chemicals supplied by Merck (Darmstadt, Germany). High-quality Milli-Q water (resistance higher than 18 MW cm) was used for preparing the solutions and buffers. Solutions of CAT, Na 2 S 2 O 5 ,i odophenethylmaleimide, and hydroxylphenethylmaleimide were prepared immediately before use. TLC plates were developed in 1,2-dichlorethane (BDH chemicals, Poole Dorset, UK) followed by heating. Distribution of radioactivity along the TLC plates and ITLC strips was measured using aC yclone Storage phosphor system and analyzed with the OptiQuant image analysis software (PerkinElmer,W altham, USA). The radiochemical purity of the labeled Affibody molecule construct was analyzed using 150-771 DARK GREEN, Te c-control Chromatography Strips (ITLC) from Biodes medical system (New York, USA). Size-exclusion chromatography was performed on disposable NAP-5 columns (Amersham Pharmacia Biotech AB, Uppsala, Sweden) according to the manufacturer's instructions. Cellular experiments were performed using human ovarian carcinoma cells, SKOV-3 (ATCC, purchased via LGCPromochem, Borås, Sweden). Ketalar (ketamine, 50 mg mL À1 ,P fizer,N ew York, USA), Rompun (xylazin, 20 mg mL . TLC was carried out on Merck precoated 60 F254 aluminum plates (0.2 mm) using UV light (254 nm). Charring with 8% phosphomolybdic acid (PMA) in absolute EtOH or 0.5 %n inhydrine in EtOH (95 %) was used for visualization. Flash column chromatography was performed using silica gel 60 (0.040-0.063 mm, Merck). Analytical liquid chromatography/mass spectrometry (LC-MS) was performed on aG ilson HPLC system with aF innigan AQA-quadropole mass spectrometer (Gilson Inc.,M iddleton, USA) using aC 18 (5 mm, 4.6 100 mm) column, with a5 min gradient of 60-100 %C H 3 CN in 0.05 %a qH COOH as mobile phase at af low rate of 4mLmin À1 .A ll starting materials and reagents were purchased from Sigma-Aldrich Sweden (Stockholm) and used without further purification. All synthesized molecules are > 95 %p ure as shown by TLC, analytical LC-MS, and NMR spectroscopy.T he radioactivity was measured using an automated gamma counter with a1 480 Wizard three-inch NaI (Tl) detector (Wallac Oy,T urku, Finland). The production of Z HER2:2395 was described earlier. [20] Synthesis of N-(4-bromophenethyl)phthalimide (4)
To as tirred solution of 3 (1.0 g, 5mmol in 50 mL diethyl ether) was added phthalic anhydride (741 mg, 5mmol). The mixture was stirred for 2h.A fterwards, aw hite precipitate (carbamoylbenzoic acid) was collected after filtration and washed with cold diethyl ether (3 30mL). The acid was dissolved in glacial CH 3 COOH (15 mL) and heated at 65 8Cf or 3h.T he mixture was cooled to rt and was allowed to precipitate overnight. 
Synthesis of N-[(tri-n-butylstannyl)phenethyl]phthalamide (5)
Ap ressure-resistant 50 mL glass tube was loaded with 4 (500 mg, 
Synthesis of 4-tri-n-butylstannylphenethylamine (6)
To ap ressure-resistant 50 mL glass tube containing 5 (600 mg, 1.1 mmol), CH 3 NH 2 (10 mL, 33 %i na bsolute EtOH) was added. The tube was capped and heated to 60 8Cf or 2h.A fter cooling, the solvent was removed leaving aw hite solid. NaOH (20 mL, 2.5 m) was added and then extracted with diethyl ether (3 30mL). The organic phases were combined, dried over MgSO 4 ,a nd evaporated leaving the desired product, [2] 
Synthesis of N-[4-iodophenethyl]-maleimide (9)
To as tirred solution of 8 (124 mg, 0.5 mmol) in diethyl ether (10 mL), maleic anhydride (57 mg, 0.6 mmol, 1.2 equiv) was added, and the reaction was left stirring for 2h.T he precipitate was collected and dissolved in glacial CH 3 COOH (10 mL) and heated at 65 8Cf or 3h.The mixture was cooled to rt and was allowed to precipitate overnight. 
Radioiodination of iodophenethylmaleimide (IPEM)
The precursor was radioiodinated using CATasanoxidant. Typically 125 I( 10 mL, 1MBq mL À1 )w as added to the precursor 7 (3 mL, dissolved in EtOH at ap redetermined concentration) and solvent (10 mL, 5% HOAc in MeOH). To the mixture, CAT( 10 mL, 4 mg mL À1 in Milli-Q H 2 O) was added. The reaction proceeded for ap redetermined time and then quenched by ad ouble molar excess of Na 2 S 2 O 5 (6 mg mL À1 in Milli-Q H 2 O).
The dependence of labeling yield on the amount of precursor and reaction time was determined by varying one parameter at at ime. The amount of 7 varied between 0.01-15 mga nd the reaction time varied between 1-10 min. When the amount of 7 varied, the reaction time was set at 10 min. When the reaction time was varied, the amount of 7 remained constant (3 mg).
Silica gel 60 F254 TLC plates (20 100 mm, elution path 80 mm) (Merck) were used for analysis. As eluent,1,2-dichlorethane was used. In this system, iodide remains at the origin while IPEM has an R f of 0.4. The reaction mixture (1.8-2 mL) was applied to the ITLC plate, which was then left to evaporate spontaneously before being developed in the eluent. All experiments were done at least in duplicate. Blank experiments were performed where 5% HOAc in MeOH (3 mL) was used instead of 7.
Conjugation of IPEM (2) to prereduced Z HER2:2395
Before labeling, the Affibody molecule solution in PBS was treated with dithiothreitol (DTT,M erck) in order to reduce spontaneously formed disulfide bonds. Typically,t he stock Affibody solution (50 mL, 10 mg mL
À1
)i nP BS was mixed with DTT (350 mL) in PBS to get afinal concentration of 50 mm DTT.The mixture was incubated at 40 8Cf or 3h at rt. Thereafter the mixture was applied to NAP-5 size-exclusion columns, pre-equilibrated, and eluted with well-degassed 0.2 m NH 4 OAc (pH 6.3), containing 0.04 m sodium ascorbate. The first 900 mLo ft he high molecular weight (HMW) fraction was used for labeling. The reduced Affibody was used for labeling approximately 10-15 min after reduction. Compound 7 was radioiodinated as described above. To get the best conjugation conditions, the Affibody:IPEM molar ratio was varied between 1:1, 2:1, and 3:1. Z HER2:2395 was added in varying amounts to the 125 I-IPEM solution (2 mgo f7 )a nd incubated at rt. Small fractions (~1.5 mL) were analyzed on ITLC silica gel strips developed in 80 %a cetone in H 2 O, at 20, 40, and 60 min. In this system, the Affibody molecule remains at the origin, and IPEM and iodide have an R f of 1.0. After conjugation, 125 I-IPEM-Z HER2:2395 was purified using an NAP-5 size-exclusion column pre-equilibrated with PBS. The mixture (1.6 mL) was analyzed using radio-ITLC to determine radiochemical purity of the final product. All experiments were done in duplicate.
Stability test
The stability of radioiodine coupling to the Z HER2:2395 was assessed by incubating the solution for at 4 8Cf or 24 ha nd thereafter at rt for 4h.S tability was further analyzed by incubating the radioiodinated Z HER2:2395 with 2 m NaI or 30 %E tOH, both for 1h.T he labeling was done as described above and purified via NAP-5 size-exclusion chromatography.
125
I-IPEM-Z HER2:2395 was added in equal volume (50 mL) to Eppendorf tubes containing 2 m NaI in PBS, and the solution was incubated for 1h.F or the stability test in EtOH, 95 % EtOH (30 mL) was added to the sample (70 mL) in Eppendorf tubes, and the solution was incubated for 1h.A ll experiments were done in duplicate and analyzed using ITLC strips.
Labeling of HPEM
Labeling of HPEM was performed as previously described. [26] In brief, HPEM precursor solution(5 mg) in 5% HOAc in MeOH was mixed with 125 I( 10 mL). To the mixture, aq CATs olution (10 mL, 4 mg mL conjugates to HER2 were evaluated using HER2-expressing SKOV-3 ovarian cancer cells as previously described. [27] Briefly,asolution of (1 10 6 cells/dish). To block the receptors, an excess of nonlabeled Z HER2:2395 was added 5min before applying the labeled conjugate to one group of dishes. The cells were incubated in 37 8Cf or 1hin ah umidified incubator;t hereafter,t he cell media was collected, and the cells were detached with trypsin-EDTAs olution (0.5 mL, 0.5 %t rypsin, 0.02 %E DTAi nb uffer,B iochrom AG, Berlin, Germany). Then the complete medium (0.5 mL) was added to every dish, and cells were resuspended and collected. The percentage of cell-bound radioactivity was calculated by measuring the radioactivity in the media and the cells. I-IHPEM-Z HER2:2395 by SKOV-3 cells was studied according to am ethod previously described and validated. [27] The labeled compounds (1.99 ng/dish, 27 pM) were added to each dish, with three dishes per time point per conjugate (1 10 6 cells/dish). The cells were incubated at 37 8C, 5% CO 2 .A t predetermined time points (1, 2, 4, 8, and 24 ha fter the start of incubation), the media from the dishes was collected, and the cells were washed with ice-cold serum-free medium. The cells were then treated with 0.2 m glycine buffer containing 4 m urea, pH 2.5, www.chemistryopen.org (0.5 mL) for 5min on ice. The solution was collected, and the cells were washed additionally with glycine buffer (0.5 mL), the fractions were pooled together.T he radioactivity from the acid wash fractions was considered to be membrane bound. The cells were then incubated at 37 8Cf or at least 30 min with 1 m NaOH (0.5 mL).The alkaline solution was collected, the cell dishes were washed with an additional NaOH (0.5 mL), and the alkaline fractions were pooled. The radioactivity in the alkaline fractions was considered internalized. The percent of internalized radioactivity was calculated for each fraction at each time point.
Biodistributions study in NMRI mice
All animal experiments were planned and performed according to the Swedish national legislation on the protection of laboratory animals, and the study plans were approved by the Uppsala committee for animal research ethics (Uppsala djurfçrsçksetiskanämd, permission C224/10 given to A. Orlova). Female NMRI mice (10-12 weeks old at arrival) were acclimatized for one week at the Rudbeck Laboratory animal facility.G roups of four animals per time point were used for the biodistribution study.A nimals were intravenously injected with 30 kBq of either ) was injected intraperitonealy.T he mice were sacrificed by heart puncture. Blood was collected, and organ samples were excised. The samples were put in preweighed plastic vials. The samples were weighed, and their radioactivity was measured. The uptake in tissue and organ were calculated as percent injected activity per gram tissue (% IA g À1 ). For the gastrointestinal tract and the carcass, injected activity per whole sample was calculated (% IA g À1 ).
